mRNA Expression of the Angiogenesis Markers VEGF and CD105 (Endoglin) in Human Breast Cancer

Background: Both VEGF and CD105 (endoglin) have been identified as markers of tumor angiogenesis and prognosis in breast cancer. They have always been studied in this kind of tumor by means of immunological methods. Objective: To study, by means of reverse-transcription polymerase chain reaction (RT...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2004-05, Vol.24 (3A), p.1581-1585
Main Authors: Gomez-Esquer, F, Agudo, D, Martinez-Arribas, F, Nunez-Villar, M-J, Schneider, J
Format: Article
Language:English
Subjects:
Antigens, CD
Biological and medical sciences
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Breast Neoplasms - pathology
Endoglin
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Neovascularization, Pathologic - genetics
Neovascularization, Pathologic - metabolism
Receptors, Cell Surface
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - biosynthesis
RNA, Messenger - genetics
Tumors
Vascular Cell Adhesion Molecule-1 - biosynthesis
Vascular Cell Adhesion Molecule-1 - genetics
Vascular Endothelial Growth Factor A - biosynthesis
Vascular Endothelial Growth Factor A - genetics
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Both VEGF and CD105 (endoglin) have been identified as markers of tumor angiogenesis and prognosis in breast cancer. They have always been studied in this kind of tumor by means of immunological methods. Objective: To study, by means of reverse-transcription polymerase chain reaction (RTPCR), the expression of VEGF and CD105 (endoglin) at the mRNA level in a series of breast cancers and to correlate the results obtained with all available clinical and biological features of the tumors. Materials and Methods: Fresh tumor tissue from 103 previously untreated breast cancer patients was studied for VEGF and CD105 (endoglin) expression. In addition, the following parameters were determined in all tumors: DNA ploidy by means of flow cytometry; hormone receptor (ER & PR), Ki67, c-erb-B2 and p53 expression by means of immunohistochemistry; and h-MAM (mammaglobin) expression by means of RT-PCR. Classical prognostic parameters of the tumors, such as histological and nuclear grade or axillary lymph node invasion, were also included into the statistical analysis. Results: VEGF mRNA expression levels above the 25th percentile were significantly (p10%) and aneuploidy of the tumors and inversely with estrogen receptor expression (p
ISSN:0250-7005
1791-7530